Viking Therapeutics：市场可能对维持期数据不以为意 (NASDAQ:VKTX)
· seekingalpha.com
VKTX股票前景：VK2735肥胖/糖尿病催化剂时间线、口服与注射差异化、现金消耗及稀释风险。
Viking Therapeutics ( VKTX ) is continuing on with its development of VK2735, an incretin with potential for weight loss and diabetes, among other indications. ...